HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Double blind glucocorticoid controlled trial of samarium-153 particulate hydroxyapatite radiation synovectomy for chronic knee synovitis.

AbstractBACKGROUND:
Samarium-153 particulate hydroxyapatite (Sm-153 PHYP) is a relatively new radiation synovectomy agent developed for the treatment of chronic synovitis. Although it has been shown that the levels of unwanted extra-articular radiation are lower after intra-articular injection of Sm-153 PHYP than yttrium-90 colloid, its clinical efficacy has not been rigorously studied.
OBJECTIVES:
To establish whether Sm-153 PHYP radiation synovectomy results in a clinically useful benefit sustained at one year.
METHODS:
In a randomised double blind study, patients received either intra-articular 40 mg triamcinolone hexacetonide alone or 40 mg triamcinolone hexacetonide combined with Sm-153 PHYP in an outpatient clinic.
RESULTS:
Sixty patients (28 male, 32 female), median age 51 (18-75) with chronic knee synovitis were studied. Diagnoses included: rheumatoid arthritis (n=29); psoriatic arthritis (n=9); ankylosing spondylitis (n=3); reactive arthritis (n=2); undifferentiated seronegative oligoarthritis (n=13) and miscellaneous inflammatory conditions (n=4). More patients who received Sm-153 PHYP/triamcinolone hexacetonide sustained clinical benefit a year after treatment compared with patients who received corticosteroid alone (12 of 31 (39%) v 6 of 29 (21%), a difference of 18% more patients (95% CI -5% to 41%)) though the difference was not significant (chi(2)=2.31, 0.2>p>0.1, n=60). Despite the variation in injected activity (median 563 MBq, range 218-840 MBq), there was no obvious relation between low levels of injected activity (<555 MBq) and relapse within 12 months of treatment (chi(2) =2.61, 0.2>p>0.1, n=31).
CONCLUSIONS:
There was no clear beneficial clinical effect of combined Sm-153 PHYP/triamcinolone hexacetonide injection over triamcinolone hexacetonide alone a year after treatment for chronic knee synovitis.
AuthorsE K O'Duffy, G P Clunie, D Lui, J C Edwards, P J Ell
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 58 Issue 9 Pg. 554-8 (Sep 1999) ISSN: 0003-4967 [Print] ENGLAND
PMID10460188 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Hydroxyapatites
  • Radioisotopes
  • samarium hydroxyapatite
  • Samarium
  • Triamcinolone Acetonide
  • triamcinolone hexacetonide
Topics
  • Administration, Topical
  • Adult
  • Aged
  • Anti-Inflammatory Agents (therapeutic use)
  • Chronic Disease
  • Combined Modality Therapy
  • Double-Blind Method
  • Female
  • Glucocorticoids
  • Humans
  • Hydroxyapatites (therapeutic use)
  • Knee Joint
  • Male
  • Middle Aged
  • Radioisotopes (therapeutic use)
  • Samarium (therapeutic use)
  • Synovitis (radiotherapy)
  • Triamcinolone Acetonide (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: